Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on AstraZeneca (AZN) to 11,000 GBp from 10,500 GBp and keeps a Sell rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Trump Trade: White House releases details on ‘Great Healthcare Plan’
- Drugmakers concerned about legal risk with FDA review program, Reuters reports
- White House releases details on Trump ‘Great Healthcare Plan’
- Former Emergent BioSolutions CEO sued by NY AG for insider trading
- AstraZeneca’s Imfinzi Post‑Marketing Study in Japan: What the Completed Safety Tracking Means for Investors